Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)

Christian D. Peters,Krista Dybtved Kjaergaard,Jens Dam Jensen,Kent L. Christensen,Charlotte Strandhave,Ida Noerager Tietze,Marija Kristina Novosel,Bo Martin Bibby,Bente Jespersen

Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)

2015

Christian D. Peters
Krista Dybtved Kjaergaard
Jens Dam Jensen
Kent L. Christensen
Charlotte Strandhave
Ida Noerager Tietze
Marija Kristina Novosel
Bo Martin Bibby
Bente Jespersen

Background and Aim Little is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan.

Keywords:

Urology
Angiotensin Receptor Antagonists
Placebo
Pharmacology
Irbesartan
Hemodialysis
Hemodynamics
Biphenyl compound
Angiotensin receptor
Medicine
Tolerability

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations